`Patent Owner’s Mandatory Notices
`
`
`
`
`
`
`
`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`_________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`
`
`
`FRESENIUS KABI USA, LLC
`Petitioner
`
`v.
`
`CEPHALON, INC.
`Patent Owner
`
`_____________
`
`Case IPR2016-00098
`Patent No. 8,791,270
`
`_____________________
`
`PATENT OWNER’S MANDATORY NOTICES
`PURSUANT TO 37 C.F.R. § 42.8
`
`
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`United States Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`
`
`
`
`IPR2016-00098
`Patent Owner’s Mandatory Notices
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8, Patent Owner, Cephalon, Inc. (“Cephalon”),
`
`hereby submits the following mandatory notices.
`
`I.
`
`
`
`REAL PARTY IN INTEREST (37 C.F.R. § 42.8(b)(1))
`
`Cephalon is the patent owner and real party-in-interest. Cephalon is an
`
`indirect wholly owned subsidiary of Teva Pharmaceuticals Industries Ltd.
`
`II. RELATED MATTERS (37 C.F.R. § 42.8(b)(2))
`
`A.
`
`Judicial Matters
`
`U.S. Patent No. 8,791,270 (“’270 Patent”) has been or is currently at issue in
`
`the following district court litigation:
`
` Cephalon, Inc. v. Apotex, Inc., No. 1:15-cv-00404-GMS (D. Del.);
`
` Cephalon, Inc. v. Panacea Biotec, Ltd., No. 1:15-cv-00735-GMS (D.
`
`Del.);
`
` Cephalon, Inc. v. Nang Kuang Pharm. Co., Ltd., 1:14-cv-01117-GMS
`
`(D. Del.); and
`
` Cephalon, Inc. v. Nang Kuang Pharm. Co., Ltd., No. 1:14-cv-05180-
`
`KAM-RER (E.D.N.Y.).
`
`Additionally, the following Delaware district court litigations involving the
`
`’270 Patent (and/or related patents) were consolidated into In re Bendamustine
`
`Consol. Cases, No. 1:13-cv-02046-GMS (D. Del.):
`
`
`
`1
`
`
`
`
`
`IPR2016-00098
`Patent Owner’s Mandatory Notices
`
` Cephalon Inc. v. Eagle Pharms. Inc., No. 1:13-cv-01738-GMS (D.
`
`Del.);
`
` Cephalon Inc. v. Hetero Labs Ltd., 1:13-cv-02046-GMS (D. Del.);
`
` Cephalon Inc. v. Agila Specialties Inc., 1:13-cv-02080-GMS (D.
`
`Del.);
`
` Cephalon Inc. v. InnoPharma Inc., No. 1:13-cv-02081-GMS (D.
`
`Del.);
`
` Cephalon, Inc. v. Dr. Reddy’s Labs., Ltd., No. 1:13-cv-02082-GMS
`
`(D. Del.);
`
` Cephalon, Inc. v. Glenmark Pharms. Ltd., No. 1:13-cv-02093-GMS
`
`(D. Del.);
`
` Cephalon Inc. v. Hospira Inc., No. 1:13-cv-02094-GMS (D. Del.);
`
` Cephalon, Inc. v. Accord Healthcare, Inc., 1:13-cv-02095-GMS (D.
`
`Del.);
`
` Cephalon, Inc. v. Sun Pharma Global FZE, No. 1:13-cv-02096-GMS
`
`(D. Del.);
`
` Cephalon Inc. v. Sandoz Inc., No. 1:13-cv-02104-GMS (D. Del.);
`
` Cephalon, Inc. v. Actavis LLC f/k/a Actavis Inc., 1:14-cv-00122-GMS
`
`(D. Del.);
`
`2
`
`
`
`
`
`
`
`
`
`IPR2016-00098
`Patent Owner’s Mandatory Notices
`
` Cephalon, Inc. v. Sun Pharma Global FZE, No. 1:14-cv-00333-GMS
`
`(D. Del.);
`
` Cephalon, Inc. v. Dr. Reddy's Labs., Ltd., No. 1:14- cv-00334-GMS
`
`(D. Del.);
`
` Cephalon, Inc. v. Emcure Pharms., Ltd., No. 1:14-cv-00335-GMS (D.
`
`Del.);
`
` Cephalon, Inc. v. Pharmasci. Inc., 1:14-cv-00568-GMS (D. Del.);
`
` Cephalon Inc. v. InnoPharma Inc., No. 1:14-cv-00590-GMS (D.
`
`Del.);
`
` Cephalon, Inc. v. Breckenridge Pharm., Inc., 1:14-cv-00671-GMS (D.
`
`Del.);
`
` Cephalon Inc. v. Eagle Pharms. Inc., No. 1:14-cv-01042-GMS (D.
`
`Del.);
`
` Cephalon, Inc. v. Eurohealth Int’l Sarl, 1:14-cv-01045-GMS (D.
`
`Del.);
`
` Cephalon, Inc. v. Sagent Pharms., Inc., 1:14-cv-01116-GMS (D.
`
`Del.);
`
` Cephalon, Inc. v. Agila Specialties, Inc., No. 1:14-cv-01237-GMS (D.
`
`Del.);
`
`3
`
`
`
`
`
`
`
`
`
`IPR2016-00098
`Patent Owner’s Mandatory Notices
`
`
`
` Cephalon Inc. v. InnoPharma Inc., No. 1:14-cv-01238-GMS (D.
`
`Del.);
`
` Cephalon Inc. v. Sandoz Inc., 1:14-cv-01239-GMS (D. Del.);
`
` Cephalon, Inc. v. Dr. Reddy’s Labs., Ltd., No. 1:14-cv-01241-GMS
`
`(D. Del.);
`
` Cephalon Inc. v. Hospira Inc., No. 1:14-cv-01242-GMS (D. Del.);
`
` Cephalon, Inc. v. Sun Pharma Global FZE, No. 1:14-cv-01243-GMS
`
`(D. Del.);
`
` Cephalon, Inc. v. Wockhardt Bio Ltd., 1:14-cv-01332-GMS (D. Del.);
`
` Cephalon Inc. v. Sandoz Inc., No. 1:15-cv-00178-GMS (D. Del.); and
`
` Cephalon, Inc. v. Dr. Reddy’s Labs., Ltd., No. 15-cv-00179-GMS (D.
`
`Del.).
`
`B. Administrative
`
`
`
`The ’270 Patent is the subject of a petition for Inter Partes Review in
`
`IPR2016-00026. The Board has not yet decided whether to institute review on that
`
`petition.
`
`The ’270 Patent claims priority to U.S. Patent No. 8,436,190, which is
`
`currently under review in IPR2015-00503.
`
`
`
`4
`
`
`
`
`
`IPR2016-00098
`Patent Owner’s Mandatory Notices
`
`
`
`The ’270 Patent also claims priority to U.S. Patent No. 8,461,350 and U.S.
`
`Provisional Patent Application No. 60/644,354. U.S. Patent Nos. 8,895,756,
`
`8,436,190 and 8,609,863 also claim priority to U.S. Provisional Patent Application
`
`No. 60/644,354.
`
`Petitioner filed a Petition for Inter Partes Review of U.S. Patent No.
`
`8,895,756 in IPR2016-00111. The Board has not yet decided whether to institute
`
`review on that petition.
`
`Pending U.S. Patent Application No. 14/845,564 claims the benefit of the
`
`’270 Patent.
`
`III. LEAD AND BACKUP COUNSEL (37 C.F.R. § 42.8(b)(3))
`
`LEAD COUNSEL
`
`BACK-UP COUNSEL
`
`Soumitra (Sam) Deka
`
`(Reg. No. 70,252)
`
`KAYE SCHOLER LLP
`
`Aaron Stiefel
`
`(Pro Hac Vice pending)
`
`KAYE SCHOLER LLP
`
`Two Palo Alto Square
`
`250 West 55th Street
`
`3000 El Camino Real, Suite 400
`
`New York, NY 10019-9710
`
`Palo Alto, CA 94306
`
`Tel: (212) 836-8000
`
`Fax: (212) 836-8689
`
`
`
`Tel: (212) 836-8000
`
`Fax: (212) 836-8689
`
`aaron.stiefel@kayescholer.com
`
`5
`
`
`
`
`
`IPR2016-00098
`Patent Owner’s Mandatory Notices
`
`
`soumitra.deka@kayescholer.com
`
`
`
`IV. SERVICE INFORMATION (37 C.F.R. § 42.8(b)(4))
`
`Please direct all correspondence to counsel using the contact information
`
`above. Petitioner consents to service by electronic mail at
`
`soumitra.deka@kayescholer.com and aaron.stiefel@kayescholer.com.
`
`
`
`Dated: November 18, 2015
`
`Respectfully Submitted,
`KAYE SCHOLER LLP
`
`
`
`/s/ Soumitra Deka
`
`
`
`
`Soumitra (Sam) Deka
`(Reg. No. 70,252)
`Two Palo Alto Square
`3000 El Camino Real, Suite 400
`Palo Alto, CA 94306
`Tel: (212) 836-8000
`Fax: (212) 836-8689
`
`Attorneys for Patent Owner
`
`6
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2016-00098
`Patent Owner’s Mandatory Notices
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing document,
`
`PATENT OWNER’S MANDATORY NOTICES PURSUANT TO 37 C.F.R.
`
`§ 42.8, was served via electronic mail and by FedEx on November 18, 2015 to the
`
`following counsel of record for the Petitioner:
`
`
`
`
`
`
`
`
`
`Lawrence Sung
`Neal Seth
`WILEY REIN LLP
`nseth@wileyrein.com
`lsung@wileyrein.com
`
`WILEY REIN LLP
`ATTN: Patent Administration
`1776 K Street NW
`Washington, DC 20006
`
`
`
`
`
`
`
`/s/ Soumitra Deka
`Soumitra (Sam) Deka
`(Reg. No. 70,252)
`KAYE SCHOLER LLP
`
`
`Dated: November 18, 2015
`
`
`
`
`
`
`
`7
`
`